Science Current Events | Science News | Brightsurf.com
 
Email a Friend Send to a friend
Printer Friendly Print Breast cancer and hormone therapy -- A looking-glass mirror?

Breast cancer and hormone therapy -- A looking-glass mirror?

July 25, 2007

The medical community has been debating for many years whether, and to what extent, postmenopausal hormone therapy (HT) use is associated with a higher risk of breast cancer, says Professor Amos Pines, President of the International Menopause Society. Although it is agreed that long-term HT slightly increases that risk, the definition of long-term use is still unclear, particularly in view of data showing that it may vary significantly by type of HT (estrogen-alone vs. estrogen-progestin, brand of progestin, dosage). A new study from the Kaiser Permanente health plan[1] raises the question whether trends in breast cancer incidence and use of HT over the past 25 years may be directly linked.

The Women's Health Initiative (WHI) trial was a landmark in menopause medicine since it provided information based on the best available study methodology[2]. By adopting its results as the ultimate source of information, many organizations, medical societies and health authorities actually declared that data derived from observations in the postmenopausal population are less valuable. Nevertheless, during the past few months, several studies have used databases on the incidence of breast cancer, on the one hand, and sales of HT on the other hand, in order to suggest a direct link between trends of hormone use and the number of newly diagnosed breast cancer patients. While such information, by itself, is very important and interesting, conclusions must be drawn with great caution. It is tempting to simplify the observed year-by-year figures on HT use and breast cancer incidence and establish a 'mirror glass' equation: the more postmenopausal hormone use, the more breast cancer, and vice versa. But human biology is far too complicated and the pathophysiology of breast cancer is far too complex to adopt such a mechanistic approach, as the authors of those studies and related Editorials rightly say.




The mere fact that the incidence of lung cancer is higher among people carrying a lighter in their pocket does not mean that lighters cause lung cancer. Thus, having two parallel time trends, for breast cancer incidence and for hormone use, still makes it necessary to investigate further in order to better understand if and how those trends could be linked. For example, a third important player has now been added, namely the rate of mammography screening, which has proved to have similar fluctuations as HT use and breast cancer incidence1. According to the Kaiser Permanente registry[1], the rate of women aged 45-59 undergoing screening mammography in 2002-2004 (post-WHI period) decreased from 48% to 44%. Thus, awareness of the need for periodic breast examinations may ease, and the likelihood of women coming to be examined may decrease in a population that uses HT less frequently, which could lead to under-diagnosis of breast cancer.

On the other hand, the 28% increase in breast cancer incidence between the early 1980s and the early 1990s observed in the Kaiser Permanente cohort probably reflects the outcome of implementation of the mammography screening program during that period. The largest group among HT users in most of the countries (excluding the USA) has always been women younger than 60 years. The Kaiser Permanente data show that, for women aged 45-59, the 70% drop in HT use (defined as dispensation of at least one hormonal prescription) in the year 2006 (post-WHI period) as compared to the year 2000 (pre-WHI period) was associated with a non-significant decrease of 4.9% in breast cancer incidence, which translates into a reduction of less than one case of breast cancer per 10,000 women per year. Furthermore, a welcome but unexplained fact is that, in younger women (age groups < 45 years and 45-59 years), the incidence of invasive breast cancer started to decrease before the year 2000 (see Figure 1 in Glass et al.[1]). The same has been shown for the incidence of localized cancers (Figure 2[1]) and the age-adjusted annual incidence rate of both estrogen receptor-positive and -negative breast cancers (Figure 3[1]). Therefore, the decrease of breast cancer incidence analyzed from different angles by Glass and colleagues cannot be attributed simply to the drop in HT use, which started after the publication of the WHI study. There must be another, non-hormonal and still unknown factor explaining, at least in part, these changes in incidence since 1998.

Professor Pines concludes that the new epidemiological data coming from the Kaiser Permanente study do have scientific merits, but may be confusing when interpreted for the lay public. Health-care providers should stay with the first-grade information coming from the WHI study when discussing this issue with their patients: breast-wise, in women younger than 60, HT (particularly estrogen-alone) is safe. Long-term use may be associated with a small increased risk, in the order of one extra case per 1000 women per year. Discontinuation of HT brings this risk back to the values for age-matched non-users after 3-5 years. Weighing the overall benefits and risks of HT in the younger postmenopausal population clearly favors the use of HT for symptomatic women.

International Menopause Society



Related Breast Cancer Current Events and Breast Cancer News Articles Breast Cancer Current Events and Breast Cancer News RSS Breast Cancer Current Events and Breast Cancer News RSS
Menopause-cardiology consensus statement on cardiovascular disease and on HRT
A menopause-cardiology consensus statement has called for direct action to prevent cardiovascular disease (CVD) in menopausal women. The statement also concludes that there is little evidence of increased CVD risk in taking HRT.

Researchers Identify Role of Gene in Tumor Development, Growth and Progression
Virginia Commonwealth University Massey Cancer Center and VCU Institute of Molecular Medicine researchers have identified a gene that may play a pivotal role in two processes that are essential for tumor development, growth and progression to metastasis.

UCLA researchers create 'fly paper' to capture circulating cancer cells
Just as fly paper captures insects, an innovative new device with nano-sized features developed by researchers at UCLA is able to grab cancer cells in the blood that have broken off from a tumor.

Fertility procedures need not delay breast cancer treatment for younger women
A new study published in the November issue of the Journal of the American College of Surgeons shows that breast cancer patients under 40 years old who undergo fertility preservation do not face a significant delay in the treatment of their disease when their care is coordinated in a timely fashion.

Coffee break: Compound brewing new research in colon, breast cancer
A compound in coffee has been found to be estrogenic in studies by Texas AgriLife Research scientists.

Drugs to treat anemia in cancer patients linked to thromboembolism
Medications frequently given to cancer patients to reduce their risk of anemia are associated with an increased risk of deep vein thrombosis or pulmonary embolism, according to new research led by Dawn Hershman, M.D, M.S., co-director of the breast cancer program at the Herbert Irving Comprehensive Cancer Center at NewYork-Presbyterian Hospital/Columbia University Medical Center.

Discovery in worms by Queen's researchers points to more targeted cancer treatment
Researchers at Queen's University have found a link between two genes involved in cancer formation in humans, by examining the genes in worms. The groundbreaking discovery provides a foundation for how tumor-forming genes interact, and may offer a drug target for cancer treatment.

FDA approved leukemia drugs shows promise in ovarian cancer cells
The drug Sprycel, approved for use by the U.S. Food and Drug Administration in patients with chronic myeloid leukemia, significantly inhibited the growth and invasiveness of ovarian cancer cells and also promoted their death, a study by researchers with UCLA's Jonsson Comprehensive Cancer Center found.

Carnegie Mellon researchers link health-care debate to risk of dying in US and Europe
The current health care debate in the United States is complicated. Trade-offs between heath care expenditures, lifestyle choices and life expectancy have been suggested but seldom clearly demonstrated.

Scientists uncover new key to the puzzle of hormone therapy and breast cancer
The use of postmenopausal hormone therapy has decreased over time in the United States, which researchers suggest may play a key role in the declining rate of atypical ductal hyperplasia, a known risk factor for breast cancer.
More Breast Cancer Current Events and Breast Cancer News Articles
New Balance Women's Lace Up X Out Breast Cancer Tech Tee (Athletic Grey, Small)

New Balance Women's Lace Up X Out Breast Cancer Tech Tee (Athletic Grey, Small)
by New Balance

The New Balance X Out Breast Caner Tee has a soft hand and clearly states how everyone feels!

1149 WOMENS VINTAGE BLACK ADJUSTABLE FATIGUE CAP w/PINK STRIPES & ''BREAST CANCER'' RIBBON

1149 WOMENS VINTAGE BLACK ADJUSTABLE FATIGUE CAP w/PINK STRIPES & ''BREAST CANCER'' RIBBON
by Rothco

A portion of these proceeds go to the Babylon Breast Cancer Coalition- For Life, For Hope, For Change, For the Future Visit www.babylonbreastcancer.org for more information.

Breast Cancer Survival Manual, Fourth Edition: A Step-by-Step Guide for the Woman With Newly Diagnosed Breast Cancer

Breast Cancer Survival Manual, Fourth Edition: A Step-by-Step Guide for the Woman With Newly Diagnosed Breast Cancer
by John Link (Author)

A completely updated edition of the definitive guide for patients with breast cancer
The new fourth edition of The Breast Cancer Survival Manual provides essential updates on treatment and care, enhancing the basic information that has made this the most trusted guide for women diagnosed with breast cancer for the past decade. This edition includes the most current advice on • getting a second opinion: why it’s important, what questions    to ask, and how to decide which team of doctors is best for you
• updates on genetic testing and how doctors are using
   the results to tailor care for each patient
• navigating new types of radiation, the herceptin
   breakthrough, and improved reconstruction surgeries
Conscious of the rapidly evolving spectrum of...

Fox Run Breast Cancer Awareness Baking Set

Fox Run Breast Cancer Awareness Baking Set
by Fox Run

Support Breast Cancer awareness in a sweet way with this five piece set. Bake cookies using the ribbon cookie cutters or cupcakes using the white paper bake cups with the pattern of pink ribbons. Decorate both with the included 4 in 1 sprinke assortement jar. The set also includes a pink silicone spoon spatula to help mix up your favorite batch of cookie dough.

Breast Cancer Awareness Ribbon Promise of a Cure Cuff Bracelet

Breast Cancer Awareness Ribbon Promise of a Cure Cuff Bracelet
by Silver Insanity

This Cuff Bracelet Will Fit up to a 8" Wrist and is 3/8" Wide Crafted of a Silver Toned Base Metal and Brought to High Polish Shine Set with a Bright Pink Breast Cancer Awareness Ribbon and Inscribed With The Phrase "Promise of a Cure"

Wrangler Women's Tough Enough To Wear Pink Breast Cancer Awareness Jacket,Pink,X-Large

Wrangler Women's Tough Enough To Wear Pink Breast Cancer Awareness Jacket,Pink,X-Large
by Wrangler

Are you tough enough to wear pink? That is the question the western industry asked 12/9/05 at the Wrangler National Finals Rodeo (Wrangler NFR), the "Super Bowl of pro rodeo," as it launched Tough Enough to Wear Pink (TETWP). TETWP is a multi-year, western-industry-wide fundraiser to raise awareness and funds for breast cancer research. TETWP partners are ponying up to support this cause by manufacturing pink merchandise with proceeds benefiting breast cancer research. By wearing this Tough Enough to Wear Pink shirt you are helping in the fight against breast cancer. This TETWP shirt is a pink cotton plaid. Import. Tough Enough to Wear Pink. long sleeve zip front jacket with zippered front slash pockets and the breast cancer embroidery on left chest. 100% Polyester Fleece/100% Nylon...

Raymond Geddes National Breast Cancer Foundation Pen (67709)

Raymond Geddes National Breast Cancer Foundation Pen (67709)
by Raymond Geddes

Breast Cancer Awareness Pen, Join Geddes in supporting the National Breast Cancer Foundation and the fight against Breast Cancer. Assortment contains pink pens with pink ribbons. Retractable, black in pen ink. 5 1/2" long.

Just Get Me Through This!: The Practical Guide to Breast Cancer

Just Get Me Through This!: The Practical Guide to Breast Cancer
by Deborah A. Cohen (Author), M.D., Robert M. Gelfand (Author)



Find the Cure Pink Breast Cancer Awareness Wristband

Find the Cure Pink Breast Cancer Awareness Wristband
by sci

Find The Cure Pink Breast Cancer Awareness wristband

Sunbeam Camelot Microplush Heated Throw, Breast Cancer Awareness Pink

Sunbeam Camelot Microplush Heated Throw, Breast Cancer Awareness Pink
by Sunbeam

Soft comfortable fabric that you can cuddle up with anywhere in your house. Use it on the couch while curling up to read a good book or in a chair while watching your favorite show. This throw is 50"x60", with a primstyle control which features 3 warming settings and 3 hour auto-off. So turn on your warming blanket, turn off your thermostat and save on your heating bill. Warm up to a good cause! Sunbeam is joining the fight against breast cancer. Through the purchase of this pink throw, sunbeam will donate $1.00 to city of hope for breast cancer research, treatment and education* up to $25,000. Program ends april 30, 2009. "to save lives and end breast cancer forever by empowering people, ensuring quality care for all, and energizing science to find the cures." *to learn more about...

© 2009 BrightSurf.com